Sanofi to acquire Kiadis for €308M

• Sanofi (NASDAQ:SNY) inks agreement with Kiadis Pharma (OTC:KIADF), a clinical-stage biopharma developing cell-based immunotherapy products, under which SNY will make a public offer to acquire the entire share capital of Kiadis for €5.45/share, representing an aggregate adjusted equity value of €308M.
• “We believe the Kiadis ‘off the shelf’ natural killer (NK) cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches,” said John Reed, M.D., Ph.D., Global Head of R&D at Sanofi.
• Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.
• n July 2020, Sanofi licensed Kiadis’ pre-clinical K-NK004 program for potential combination for multiple myeloma.
• Subject to the completion of the offer, the company will provide the resources and capabilities necessary to accelerate the development of current Kiadis programs.
• https://seekingalpha.com/news/3629439-sanofi-to-acquire-kiadis-for-308m